Mayo Clinic proceedings
-
Biosimilars are versions of biologic drugs made by different manufacturers that can help lower spending by promoting competition. However, few biosimilars are currently available in the US. ⋯ Of 20 biosimilars that had been approved by October 2019, the median time from initiation of phase I testing to approval was 69.9 months. These findings reveal a high testing bar for approval that likely contributed to limited market entry.
-
Mayo Clinic proceedings · Oct 2020
Biography Historical Article"By Time's Fell Hand": Shakespeare and Emotional Lockdown.